

INDIAN PHARMA

Anti-Dumping Duty Likely On A Chinese Import Used By Indian Pharma Companies

The government may impose an anti-dumping duty of \$72.95 per tonne on imports of a chemical from China, used in pharmaceutical and other industries.

In its sunset review of anti-dumping duty imposed on the imports of 'sodium nitrite', the Directorate General of Antidumping and Allied Duties (DGAD) has concluded that there is "continued dumping" of the chemical from China and it is causing injury to the domestic industry.

Read more: <https://www.bloomberqunt.com/markets/2017/07/23/anti-dumping-duty-likely-on-a-chinese-import-used-by-indian-pharma-companies>

India: Mergers, Acquisitions And Joint Venture: Trends In Bio-Similar Industries

Mergers, acquisitions and joint ventures (M&As) amongst businesses are well known trends and often considered critical for the growth of a company. Additionally, M&As help to strengthen and explore market opportunities, functional and financial synergy along with ability to generate additional revenues. M&As further encourage cross-cultural growth, transfer of technical knowhow and administrative maturity and/or adaptation.

Readmore: <http://www.mondaq.com/india/x/611294/M+A+Private+equity/Mergers+Acquisitions+And+Joint+Venture+Trends+In+BioSimilar+Industries>



Indian pharma market grew at 7.5% in June amidst GST rollout concerns

The Indian pharmaceutical market grew 7.5 percent in June holding steady in the run-up to Goods and Service Tax (GST) rollout starting from July, according to market research firm AIOCD-AWACS. The growth was led by rebound of anti-infective medicines and continued momentum of the chronic segment.

Read

<http://www.moneycontrol.com/news/business/companies/indian-pharma-market-grew-at-7-5-in-june-amidst-gst-rollout-concerns-2324429.html>

More:

India aims for \$100 billion biotech industry by 2025

Serving the twin purposes of creating a globally competitive biopharmaceutical industry that addresses India's major concerns around barriers to affordable healthcare, India's Department of Biotechnology (DBT) is set to roll out biosimilar drugs for diseases such as cancer, diabetes and rheumatoid arthritis, reports The Pharma Letter's India correspondent.

Read More: <https://www.thepharmaletter.com/article/india-aims-for-100-billion-biotech-industry-by-2025>